tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Recursion Pharmaceuticals assumed with an Equal Weight at Morgan Stanley

Morgan Stanley assumed coverage of Recursion Pharmaceuticals (RXRX) with an Equal Weight rating and $5 price target Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1